Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Neubauer

Showing results (171-180 of 224) with videos related to

Pageof 23
Sort By:
Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.
Haematologica|February 13, 2023
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trialLeo Ruhnke, Christoph Röllig, Sylvia Herold, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Blood Advances|January 23, 2023
Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemiaFalk Heidenreich, Bose Falk, Henning Baldauf, et al.
Blood|January 16, 2010
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemiaCyrus Khandanpour, Christian Thiede, Peter J M Valk, et al.
Cancers|September 23, 2022
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor BoardThomas S Tarawneh, Fiona R Rodepeter, Julia Teply-Szymanski, et al.
Haematologica|January 5, 2023
Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)Christoph Rummelt, Olga Grishina, Claudia Schmoor, et al.
Pageof 23

Showing results (171-180 of 224) with videos related to

Sort By:
Pageof 23
Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.
Haematologica|February 13, 2023
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trialLeo Ruhnke, Christoph Röllig, Sylvia Herold, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Blood Advances|January 23, 2023
Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemiaFalk Heidenreich, Bose Falk, Henning Baldauf, et al.
Blood|January 16, 2010
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemiaCyrus Khandanpour, Christian Thiede, Peter J M Valk, et al.
Cancers|September 23, 2022
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor BoardThomas S Tarawneh, Fiona R Rodepeter, Julia Teply-Szymanski, et al.
Haematologica|January 5, 2023
Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)Christoph Rummelt, Olga Grishina, Claudia Schmoor, et al.
Pageof 23